![PHT-427 - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第1頁](http://file4.renrendoc.com/view/23461833496ca32751a3b44ac4031693/23461833496ca32751a3b44ac40316931.gif)
![PHT-427 - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第2頁](http://file4.renrendoc.com/view/23461833496ca32751a3b44ac4031693/23461833496ca32751a3b44ac40316932.gif)
![PHT-427 - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第3頁](http://file4.renrendoc.com/view/23461833496ca32751a3b44ac4031693/23461833496ca32751a3b44ac40316933.gif)
![PHT-427 - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第4頁](http://file4.renrendoc.com/view/23461833496ca32751a3b44ac4031693/23461833496ca32751a3b44ac40316934.gif)
下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPHT-427Cat. No.: HY-12063CAS No.: 1191951-57-1分式: CHNOS分量: 409.61作靶點: Akt作通路: PI3K/Akt/mTOR儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (122.07 mM; Need ultrasonic)Mass Solvent1
2、 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.4413 mL 12.2067 mL 24.4135 mL5 mM 0.4883 mL 2.4413 mL 4.8827 mL10 mM 0.2441 mL 1.2207 mL 2.4413 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥蔚膬湟?,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶
3、液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.10 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.10 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 PHT-427種 Akt 和 PDPK1 雙重 抑制劑,與 Akt 和
4、 PDPK1 中的 PH 結(jié)構(gòu)域有親和性,Ki 分別為 2.7 M 和5.2 M。IC50 & Target Akt PDPK12.7 M (Ki) 5.2 M (Ki)體外研究 The effects of PHT-427 on cell signaling are investigated by RPPA using a panel of 86 antibodies tophospho- and non-phosphorylated signaling protein related to PtdIns-3-K/PDPK1/Akt signaling in PC-3prostate cel
5、ls where PtdIns-3-K/PDPK1/Akt signaling is activated because of homozygous PTEN mutation.After 16 hours, a reduction is observed in phospho-Ser241-PDPK1 phospho-Thr308-Akt by both 10 M PH-427 and 0.1 M Wortmannin. Finally, phospho-Ser657-protein kinase C (PKC) and total SGK1 are decreasedby treatmen
6、t with both PHT-427 and Wortmannin. These results suggest that at 10 M PHT-427 inhibits bothAkt and PDKP1. The BxPC-3 and MiaPaCa-2 pancreatic cancer cell lines are probed by Western blottingfollowing up to 24 hr exposure to 10 M PHT-427, which is below the IC50 for cell growth inhibition of around3
7、0 M, to determine the effects of PHT-427 on of the PtdIns-3-K/PDPK1/Akt signaling pathway components1.體內(nèi)研究 Mice with BxPC-3 pancreatic, MCF-7 breast or A-549 NSCL cancer xenografts are administered PHT-427, orits analogs with a C-4, C-6 or C-8 alkyl chain by oral gavage twice a day for 10 days. The
8、results show thatPHT-427 has the greatest antitumor activity with the C-8 chain analog having less activity, and analogs with aC-4 or C-6 chain very little activity. All further antitumor studies are conducted using compound PHT-427.Plasma levels of PHT-427 following oral administration to mice of a
9、 dose of 200 mg/kg show rapidabsorption, without a lag phase, Cmax is 8.2 g/mL 1 hr following dosing, and the elimination half-life is 1.4hr with a terminal PHT-427 concentration of 0.1 g/mL 10 hr after dosing. The plasma concentration of PH-427 is above the level which gave inhibition of Akt and PD
10、PK1 signaling in cells of 10 M (4 g/mL) for atleast 3 hr 1.PROTOCOLCell Assay 1 Panc-1 cells stably transfected with green fluorescent protein (GFP) tagged Akt or PDKP1 PH domains areserum starved in phenol red free growth medium on glass-bottom 96-well imaging plates for 16 hours. Theyare then trea
11、ted with PHT-427 at 1, 5, and 10 M or PI-103 for 4 hr, and stimulated with 50 ng/mL IGF-1 for10 min. Images are taken before and after IGF-1 treatment using an IN Cell Analyzer 1000 instrument with aNikon Plan Fluor ELWD 20X/0.45 objective loaded and using a 300msec exposure time 1.MCE has not indep
12、endently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Female C57Bl/6 mice are administered PHT-427 as a single oral dose of 200 mg/kg. The mice are killed atdifferent times (3 mice at each time point), blood collected into heparinized tubes and p
13、lasma prepared andstored frozen at -80C. For assay 0.2 mL plasma is mixed with 0.2 mL of 0.1 M sodium phosphate buffer, pH4.0, and extracted for 1 hr by inversion with 1 ml ethyl acetate. After centrifugation 0.8 mL of the organic layeris removed, evaporated under N2 and redissolved in 0.2 mL ethano
14、l and 10 L injected onto a WatersQuattro Ultima tandem mass spectrometer using a Phenomenex Luna 3.0 m, 2.050 mm C8 analytical2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEcolumn with detection and quantification by multiple reaction monitoring with the mass spectrometeroperating in electrospray
15、positive ionization mode.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 J Funct Foods. 2019 Feb.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Meuillet EJ, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent proteinkinase 1 pleckstrin homology domain inhibitor. Mol Canc
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 購物中心土地居間服務(wù)合同
- 夏季高溫對電力施工的安全措施
- 臨時活動場所空調(diào)安裝技術(shù)措施
- 砌體工程冬期施工技術(shù)支持措施
- 2025年度大型活動臨時綠植布置合同3篇
- 二零二五年度新能源儲能系統(tǒng)設(shè)計費合同模板下載2篇
- 2025年煤炭進出口居間代理業(yè)務(wù)合同樣本
- 二零二五年度私募基金公司投資風(fēng)險控制保密合同
- 2025年二手車交易市場資產(chǎn)轉(zhuǎn)讓協(xié)議
- 標(biāo)準(zhǔn)泵采購合同2025年
- 學(xué)習(xí)解讀2025年印發(fā)《教育強國建設(shè)規(guī)劃綱要(2024-2035年)》課件
- 全過程造價咨詢服務(wù)的質(zhì)量、進度、保密等保證措施
- 縣城屠宰場建設(shè)可行性研究報告
- 25學(xué)年六年級數(shù)學(xué)寒假作業(yè)《每日一練》
- 2025高考數(shù)學(xué)一輪復(fù)習(xí)-第8章-第3節(jié) 圓的方程【課件】
- DB3301T 1088-2018 杭州龍井茶栽培技術(shù)規(guī)范
- 環(huán)保行業(yè)深度研究報告
- 工程機械租賃服務(wù)方案及保障措施 (二)
- 保障性住房補貼委托書范本
- DB36T 1393-2021 生產(chǎn)安全風(fēng)險分級管控體系建設(shè)通則
- 公益捐助活動影響力評估方法
評論
0/150
提交評論